Hydroxychloroquine (Plaquenil)

A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)

Also Known As:

Networked: 1043 relevant articles (104 outcomes, 139 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Costedoat-Chalumeau, Nathalie: 18 articles (12/2015 - 11/2003)
2.	Piette, Jean-Charles: 14 articles (12/2015 - 11/2003)
3.	Amoura, Zahir: 12 articles (03/2015 - 11/2003)
4.	O'Dell, James R: 8 articles (08/2013 - 05/2002)
5.	Raoult, Didier: 7 articles (01/2015 - 07/2005)
6.	Lechat, Philippe: 7 articles (11/2013 - 02/2005)
7.	Costedoat-Chalumeau, N: 6 articles (12/2015 - 09/2006)
8.	Pareek, Anil: 6 articles (11/2015 - 09/2007)
9.	Amaravadi, Ravi K: 6 articles (08/2014 - 05/2011)
10.	Moreland, Larry W: 6 articles (08/2013 - 06/2002)

Related Diseases

1.	Rheumatoid Arthritis 07/01/1999 - "Dose-loading with hydroxychloroquine is effective in early and active rheumatoid arthritis." 12/01/1993 - "Hydroxychloroquine is moderately effective in early rheumatoid arthritis." 03/01/2015 - "Recent studies showed that hydroxychloroquine (HCQ) was protective against thrombovascular events in lupus erythematosus and traditional cardiovascular risk factors in patients with rheumatoid arthritis. " 02/01/2012 - "Comparable efficacy of standardized Ayurveda formulation and hydroxychloroquine sulfate (HCQS) in the treatment of rheumatoid arthritis (RA): a randomized investigator-blind controlled study." 02/01/1995 - "Studies of the efficacy of hydroxychloroquine in rheumatoid arthritis have had methodological flaws and have failed to produce definitive results. "
2.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 09/01/2012 - "Due to multiple beneficial effects, including control of disease activity, reduction in cardiovascular events and improved survival, hydroxychloroquine is now recommended long-term for all patients with systemic lupus erythematosus. " 08/01/1994 - "To compare the relative safety and efficacy of hydroxychloroquine (HCQ) and placebo (Pl) in the treatment of the articular complaints of systemic lupus erythematosus (SLE). " 10/01/2006 - "To study the possible relationship between whole-blood hydroxychloroquine (HCQ) concentrations and clinical efficacy of HCQ in patients with systemic lupus erythematosus (SLE). " 11/01/2013 - "Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)." 03/01/2010 - "The antimalarial medication hydroxychloroquine has been proposed as a thromboprotective agent in systemic lupus erythematosus (SLE), but studies thus far have been limited by the possibility of confounding by indication. "
3.	Thrombosis (Thrombus) 01/01/1996 - "Hydroxychloroquine use is protective against future thrombosis." 04/01/2015 - "Several data suggest that hydroxychloroquine (HCQ) could play a role in the prevention of thrombosis. " 02/01/2009 - "These data are the first to confirm in a large and ethnically diverse SLE cohort that hydroxychloroquine use is protective for thrombosis." 02/01/2009 - "After adjusting for disease severity and incorporating propensity scores, hydroxychloroquine use remained significantly protective for thrombosis (OR 0.62, p = 4.91 x 10(-4)). " 09/01/2008 - "Treatment with the antimalarial drug hydroxychloroquine (HCQ) has been associated with reduced risk of thrombosis in the antiphospholipid (aPL) syndrome (APS) and, in an animal model of APS, with reduction of experimentally induced thrombosis. "
4.	Cutaneous Lupus Erythematosus 04/01/2014 - "Beneficial effect of hydroxychloroquine on cutaneous lupus erythematosus in a Japanese girl." 06/01/2012 - "Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus." 06/01/2012 - "Hydroxychloroquine (HCQ) is used as the first-line systemic treatment for severe, widespread or refractory cutaneous lupus erythematosus (CLE) in many countries. " 04/01/2012 - "Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study." 01/01/2010 - "Clinicopathological correlation supported a diagnosis of chronic cutaneous lupus erythematosus; hydroxychloroquine was initiated with good clinical response. "
5.	Arthritis (Polyarthritis) 06/01/1998 - "To study the effect of experimental diabetes and arthritis on the pharmacokinetics of hydroxychloroquine (HCQ) enantiomers in rats. " 02/08/1963 - "Results of a trial treatment of rheumatoid polyarthritis (126 cases) by hydroxychloroquine" 12/01/2000 - "Hydroxychloroquine (HCQ) is commonly prescribed for treatment of inflammatory arthritis. " 06/01/2014 - "At 1-year follow-up, 25 cases (27.5%) had progressed to RA, 3 (3.3%) cases had developed systemic lupus, 43 cases had responded to hydroxychloroquine with complete remission, five cases had developed other rheumatic diseases, and 14 cases had progressed to undifferentiated arthritis. " 02/01/2003 - "[Interstitial granulomatous dermatitis without arthritis: successful therapy with hydroxychloroquine]."

Related Drugs and Biologics

1.	Methotrexate (Mexate)
2.	Sulfasalazine (Azulfidine)
3.	Chloroquine (Aralen)
4.	Hydroxychloroquine (Plaquenil)
5.	Penicillamine (Cuprimine)
6.	Adrenal Cortex Hormones (Corticosteroids)
7.	Prednisone (Sone)
8.	Aspirin (Acetylsalicylic Acid)
9.	Antimalarials (Antimalarial Agents)
10.	Prednisolone (Predate)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Aftercare (After-Treatment)
3.	Arthroplasty
4.	Heterologous Transplantation (Xenotransplantation)
5.	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)